Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Mind Medicine

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

Two psychedelic-focused stocks stand to benefit after the FDA designated psychedelics as a top review priority.

Barchart

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investors Business Daily

1 Small-Cap Biotech That Analysts Expect to Triple

As psychedelic treatments gain traction, analysts predict triple-digit upside for this small-cap biotech stock.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Buy the Dip in This Biotech After Negative FDA News, Says Analyst

MindMed is a high-flying pre-revenue company that has more than doubled investor returns in the last 12 months.

Barchart

3 Growth Stocks Under $10 With Breakout Potential

Discover three under-the-radar biotech and medtech stocks that analysts believe could soar in 2024, each with unique growth drivers and significant upside potential.

Barchart

Up 163% YTD, Is It Too Late to Buy MindMed Stock?

Mind Medicine is a pre-revenue biopharma company that has more than doubled investor returns in 2024. Is MNMD stock a good buy today?

Barchart

MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Benzinga

Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Benzinga

Why Crypto-Related Stocks Are Trading Lower: Here Are 34 Stocks Moving Premarket

Gainers

Benzinga

This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.

Benzinga

This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket

Gainers

Benzinga

Numinus Wellness, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Numinus Wellness (OTC:NUMIF) shares closed up 13.88% at $0.20

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78

Benzinga

ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36

Benzinga

Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International

Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.

Benzinga

Psychedelic Stock Gainers And Losers From May 20, 2022

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 8.33% at $0.77

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Earnings Preview For Mind Medicine

Mind Medicine (NASDAQ:MNMD) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Mind Medicine will report an earnings per share (EPS) of $-0.05.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022

Upgrades

Benzinga

Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87

Benzinga

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedelic molecules, becoming the third city in the state to do so after Ann Arbor and Detroit. In Utah, Governor Cox signed a psychedelics research bill into law and positive legislation around psilocybin is continuing…

Benzinga

Mindset Pharma, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 6.03% at $1.23

Benzinga

Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Allied (OTC:ALID) shares closed up 4.69% at $1.34

Benzinga

Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 5.48% at $1.54

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.